本季度信息
据公司披露，荣昌生物2026年第一季度实现营业收入约6.56亿元，同比增长24.76%。同期非GAAP净利润约3.28亿元，而上年同期则为净亏损约2.54亿元，经营表现大幅好转。经营活动产生的现金流量净额约0.11亿元，相较于上年同期的-1.88亿元也显著改善。
报告期内，研发投入约2.10亿元，同比下降36.19%，占营业收入的31.98%，较去年同期水平（62.53%）下降30.55个百分点。研发支出减少主要与产品技术授权等因素相关，也在一定程度上推动了公司整体利润转正。
业务分项
（本期公告中未单独披露各业务板块业绩具体情况。）
高管解读
（本期公告中无直接披露高管对于业绩的公开表态。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.